With the 3rd generation Quantum Blue® Reader BÜHLMANN presents a compact and easy to use state-of-the-art reader for in vitro lateral flow assays. The touch screen display together with an intuitive graphic user interface enables quick navigation and easy step-by-step tutorial screens. The camera-based reading technology increases robustness of result analysis and the connectivity via ethernet port enables connecting the device to laboratory and hospital information systems. Therefore, the 3rd generation Quantum Blue® Reader is the ideal solution for fast result reporting in a near-patient environment allowing for immediate decision making leading to an optimized clinical care.
Quantum Blue® Product Portfolio
Our assay portfolio includes high-performance rapid tests for fecal calprotectin (fCAL) and therapeutic drug monitoring (TDM) of anti-inflammatory biologics.
Fecal calprotectin is an ideal non-invasive biomarker to identify intestinal inflammation throughout the gastrointestinal tract. It has the ability to distinguish organic disease like Inflammatory Bowel Disease (IBD) from non-organic disorders such as Irritable Bowel Syndrome (IBS) in patients suffering from gastrointestinal symptoms like diarrhea or chronic abdominal pain. It was shown that fecal calprotectin not only correlates well with endoscopic disease activity, but also with mucosal healing. Thus, measuring calprotectin levels in stool is a good tool to monitor disease activity and assess the treatment success in IBD patients. Further, calprotectin has shown to be a good predictor of relapse and remission in IBD patients.
With the Quantum Blue® fCAL extended and the Quantum Blue® high range we offer two lateral flow assays for quantitative determination of fecal calprotectin within 12-15 minutes. Both assays correlate very well with the gold standard laboratory method BÜHLMANN fCAL® ELISA and BÜHLMANN fCAL® turbo.
Therapeutic Drug Monitoring
In the treatment of different chronic inflammatory diseases such as IBD or Rheumatoid Arthritis (RA), drugs targeting TNF-alpha had a marked impact on the treatment success and quality of life of patients. Among anti-TNF drugs, infliximab and adalimumab are the most commonly used biologic drugs. Nevertheless, patients having suboptimal drug levels or developing antibodies against anti-TNF drugs may have worse treatment outcomes. Therefore, assays measuring drug levels and antibodies against anti-TNF drugs can identify patients who have lost response and can optimize treatment success.
With the Quantum Blue® Infliximab and Quantum Blue® Adalimumab we offer quantitative rapid tests to measure infliximab and adalimumab through levels in patient serum within 15 minutes. The Quantum Blue® Anti-infliximab and Quantum Blue® Anti-adalimumab provide a highly specific qualitative detection of antibodies against infliximab and adalimumab. Together, these rapid tests allow for quick decision making and optimization of treatment in patients suffering from chronic inflammatory diseases.
Please find a detailed overview of our Quantum Blue® product portfolio here:
Tutorial Videos available
Quantum Blue® Reader Tutorial
Quantum Blue® TDM Tutorial
Quantum Blue® fCAL Tutorial
CALEX® Cap Extraction Tutorial